GlassScriptPhysician profile
Scott G Kroll
NPI 1659960839
$2,445.13
in general payments reported to CMS, 2019-2025
27 companies · $1,073 in 2025
The $1,073 reported for 2025 was more than what 86% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $140 · 2022: $279 · 2023: $479 · 2024: $475 · 2025: $1,073.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,027.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,027.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $584.89 | 2022-2025 | |
| Novo Nordisk INC | $446.68 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $219.38 | 2021-2025 | Mounjaro, Jardiance, Emgality |
| Amgen INC. | $155.50 | 2022-2025 | Evenity, Prolia, Repatha |
| Astrazeneca Pharmaceuticals LP | $154.86 | 2022-2025 | Breztri, Farxiga, Airsupra |
| Bayer Healthcare Pharmaceuticals INC. | $126.61 | 2025 | |
| Dexcom, INC. | $74.39 | 2021-2025 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $74.06 | 2021-2023 | Tradjenta, Synjardy |
| Exact Sciences Corporation | $66.98 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Janssen Pharmaceuticals, INC | $62.88 | 2021-2022 | |
| Glaxosmithkline, LLC. | $56.62 | 2022-2023 | Trelegy Ellipta |
| Verona Pharma, INC. | $54.80 | 2025 | Ohtuvayre |
| Biohaven Pharmaceutical Holding Company LTD. | $51.57 | 2022 | |
| Phathom Pharmaceuticals, INC. | $51.36 | 2025 | Voquezna |
| Xeris Pharmaceuticals, INC. | $40.39 | 2025 | Gvoke Hypopen |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $29.21 | 2024 | Purified Cortrophin Gel |
| Ardelyx, INC. | $27.55 | 2025 | Ibsrela |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $22.40 | 2023 | |
| Abbott Laboratories | $21.29 | 2025 | Freestyle Libre 3 |
| E.R. Squibb & Sons, L.L.C. | $20.71 | 2023 | Eliquis |
| Merck Sharp & Dohme LLC | $17.06 | 2025 | Verquvo |
| Pfizer INC. | $16.61 | 2023 | |
| Bioventus LLC | $15.90 | 2022 | |
| Astellas Pharma US INC | $14.37 | 2025 | Veozah |
| Biohaven Pharmaceuticals, INC. | $14.02 | 2021 | |
| Nestle Healthcare Nutrition INC. | $13.21 | 2021 | |
| Amarin Pharma, INC. | $11.83 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Kroll listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.